These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 33460558)

  • 1. Chimeric antigen receptor T-cell therapy for the treatment of lymphoid malignancies: is there an excess risk for infection?
    Gudiol C; Lewis RE; Strati P; Kontoyiannis DP
    Lancet Haematol; 2021 Mar; 8(3):e216-e228. PubMed ID: 33460558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.
    Acharya UH; Dhawale T; Yun S; Jacobson CA; Chavez JC; Ramos JD; Appelbaum J; Maloney DG
    Expert Rev Hematol; 2019 Mar; 12(3):195-205. PubMed ID: 30793644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies.
    Freyer CW; Porter DL
    J Allergy Clin Immunol; 2020 Nov; 146(5):940-948. PubMed ID: 32771558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy.
    Gauthier J; Turtle CJ
    Curr Res Transl Med; 2018 May; 66(2):50-52. PubMed ID: 29625831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current understanding and management of CAR T cell-associated toxicities.
    Brudno JN; Kochenderfer JN
    Nat Rev Clin Oncol; 2024 Jul; 21(7):501-521. PubMed ID: 38769449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of chimeric antigen receptor T (CAR-T) cell-associated toxicities.
    Schroeder T; Martens T; Fransecky L; Valerius T; Schub N; Pott C; Baldus C; Stölzel F
    Intensive Care Med; 2024 Sep; 50(9):1459-1469. PubMed ID: 39172238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Primer on Chimeric Antigen Receptor T-cell Therapy-related Toxicities for the Intensivist.
    Ong SY; Baird JH
    J Intensive Care Med; 2024 Oct; 39(10):929-938. PubMed ID: 37899577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy.
    Hay KA
    Br J Haematol; 2018 Nov; 183(3):364-374. PubMed ID: 30407609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CAR-T cell: Toxicities issues: Mechanisms and clinical management.
    Wallet F; Sesques P; Devic P; Levrard M; Ader F; Friggeri A; Bachy E
    Bull Cancer; 2021 Oct; 108(10S):S117-S127. PubMed ID: 34920794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in CAR T Therapy for Hematologic Malignancies.
    Freyer CW; Porter DL
    Pharmacotherapy; 2020 Aug; 40(8):741-755. PubMed ID: 32383222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurological Complications of CAR T Cell Therapy.
    Landry K; Thomas AA
    Curr Oncol Rep; 2020 Jul; 22(8):83. PubMed ID: 32607727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxicities of CD19 CAR-T cell immunotherapy.
    Hirayama AV; Turtle CJ
    Am J Hematol; 2019 May; 94(S1):S42-S49. PubMed ID: 30784102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Management of adverse effects in CAR T-cell therapy].
    Goto H
    Rinsho Ketsueki; 2023; 64(9):1203-1212. PubMed ID: 37899201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infections after anti-CD19 chimeric antigen receptor T-cell therapy for hematologic malignancies: timeline, prevention, and uncertainties.
    Haidar G; Garner W; Hill JA
    Curr Opin Infect Dis; 2020 Dec; 33(6):449-457. PubMed ID: 33009139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical care management of chimeric antigen receptor T-cell therapy recipients.
    Shimabukuro-Vornhagen A; Böll B; Schellongowski P; Valade S; Metaxa V; Azoulay E; von Bergwelt-Baildon M
    CA Cancer J Clin; 2022 Jan; 72(1):78-93. PubMed ID: 34613616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CAR-T cell therapy and infection: a review.
    Bupha-Intr O; Haeusler G; Chee L; Thursky K; Slavin M; Teh B
    Expert Rev Anti Infect Ther; 2021 Jun; 19(6):749-758. PubMed ID: 33249873
    [No Abstract]   [Full Text] [Related]  

  • 17. The critical role of endothelial cell in the toxicity associated with chimeric antigen receptor T cell therapy and intervention strategies.
    Zhang Q; Zhu X; Xiao Y
    Ann Hematol; 2024 Jul; 103(7):2197-2206. PubMed ID: 38329486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy.
    Sterner RC; Sterner RM
    Front Immunol; 2022; 13():879608. PubMed ID: 36081506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers for Predicting Cytokine Release Syndrome following CD19-Targeted CAR T Cell Therapy.
    Tedesco VE; Mohan C
    J Immunol; 2021 Apr; 206(7):1561-1568. PubMed ID: 33692146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicities following CAR-T therapy for hematological malignancies.
    Hernani R; Benzaquén A; Solano C
    Cancer Treat Rev; 2022 Dec; 111():102479. PubMed ID: 36308910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.